Menelaos Pavlou

University College London

Papers

1

Total Citations

21

H-Index

1

About

Dr. Menelaos Pavlou is a leading urologic oncologist whose research centers on the surgical management of kidney cancer, with a particular focus on nephron-sparing techniques for small renal masses. His most impactful work addresses a critical gap in urologic oncology: the lack of high-level evidence comparing minimally invasive treatment options. Dr. Pavlou spearheaded the landmark NEST (Nephron Sparing Treatment) feasibility trial, a cohort-embedded randomized controlled study that directly compared percutaneous cryoablation to robot-assisted partial nephrectomy. This innovative trial design overcame the historical challenge of poor recruitment in classical RCTs for small renal masses, demonstrating that a pragmatic, embedded approach is viable for generating comparative effectiveness data. The study, which has garnered 21 citations since its 2023 publication, provides crucial feasibility data that paves the way for larger, definitive trials. By tackling the paucity of randomized evidence in this domain, Dr. Pavlou’s work is shaping clinical decision-making for patients with small renal tumors, helping to determine the optimal balance between oncologic control and renal function preservation. His contributions are instrumental in advancing evidence-based, personalized surgical care in urologic oncology.

Research Focus

Key Achievements

1
H-Index
1
Papers
21
Total Citations
21
Avg Citations/Paper
🏆 Most Cited Paper
Nephron Sparing Treatment (NEST) for Small Renal Masses: A Feasibility Cohort-embedded Randomised Controlled Trial Comparing Percutaneous Cryoablation and Robot-assisted Partial Nephrectomy
21 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 19
🏛 Institutions: University College London

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago